<?xml version='1.0' encoding='utf-8'?>
<document id="24309312"><sentence text="Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams."><entity charOffset="81-95" id="DDI-PubMed.24309312.s1.e0" text="oxazolidinones" /><entity charOffset="97-108" id="DDI-PubMed.24309312.s1.e1" text="rifamycines" /><entity charOffset="110-120" id="DDI-PubMed.24309312.s1.e2" text="macrolides" /><entity charOffset="122-138" id="DDI-PubMed.24309312.s1.e3" text="fluoroquinolones" /><entity charOffset="144-156" id="DDI-PubMed.24309312.s1.e4" text="Beta-lactams" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e0" e2="DDI-PubMed.24309312.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e0" e2="DDI-PubMed.24309312.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e0" e2="DDI-PubMed.24309312.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e0" e2="DDI-PubMed.24309312.s1.e3" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e0" e2="DDI-PubMed.24309312.s1.e4" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e1" e2="DDI-PubMed.24309312.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e1" e2="DDI-PubMed.24309312.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e1" e2="DDI-PubMed.24309312.s1.e3" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e1" e2="DDI-PubMed.24309312.s1.e4" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e2" e2="DDI-PubMed.24309312.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e2" e2="DDI-PubMed.24309312.s1.e3" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e2" e2="DDI-PubMed.24309312.s1.e4" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e3" e2="DDI-PubMed.24309312.s1.e3" /><pair ddi="false" e1="DDI-PubMed.24309312.s1.e3" e2="DDI-PubMed.24309312.s1.e4" /></sentence><sentence text="Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions" /><sentence text=" These drug interactions are a major concern in clinical practice as they may have an effect on efficacy and toxicity" /><sentence text=" This article provides an overview of all published pharmacokinetic studies on drug interactions of the commonly prescribed antimicrobial drugs oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams, focusing on systematic research"><entity charOffset="144-158" id="DDI-PubMed.24309312.s4.e0" text="oxazolidinones" /><entity charOffset="160-171" id="DDI-PubMed.24309312.s4.e1" text="rifamycines" /><entity charOffset="185-201" id="DDI-PubMed.24309312.s4.e2" text="fluoroquinolones" /><pair ddi="false" e1="DDI-PubMed.24309312.s4.e0" e2="DDI-PubMed.24309312.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24309312.s4.e0" e2="DDI-PubMed.24309312.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24309312.s4.e0" e2="DDI-PubMed.24309312.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24309312.s4.e1" e2="DDI-PubMed.24309312.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24309312.s4.e1" e2="DDI-PubMed.24309312.s4.e2" /></sentence><sentence text=" We describe drug-food and drug-drug interaction studies in humans, affecting antimicrobial drugs as well as concomitantly administered drugs" /><sentence text=" Since knowledge about mechanisms is of paramount importance for adequate management of drug interactions, the most plausible underlying mechanism of the drug interaction is provided when available" /><sentence text=" This overview can be used in daily practice to support the management of pharmacokinetic drug interactions of antimicrobial drugs" /><sentence text=" " /></document>